An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy

Journal of Molecular Medicine

Volumn 84, Issue 3, 2006, Pages 215-225

  Sipo, Isaac ^a   Picó, Almudena Hurtado ^a   Wang, Xiaomin ^a   Eberle, Jürgen ^a   Petersen, Iver ^a   Weger, Stefan ^a   Poller, Wolfgang ^a   Fechner, Henry ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Cancer gene therapy; CD95 Fas ligand; Tet On system; Tetracycline response element

Indexed keywords

DOXYCYCLINE; FAS LIGAND; TETRACYCLINE;

ADENOVIRUS VECTOR; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER THERAPY; CARCINOMA CELL; CELL DEATH; CELL LINE; CONTROLLED STUDY; CYTOLYSIS; CYTOMEGALOVIRUS; DNA RESPONSIVE ELEMENT; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; LUNG CANCER; NONHUMAN; PLASMID; RAT; REPORTER GENE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; APOPTOSIS; DOXYCYCLINE; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; HELA CELLS; HUMANS; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; PROMOTER REGIONS (GENETICS); TETRACYCLINE; TOXICITY TESTS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTORS;

EID: 33344477324     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-005-0009-1     Document Type: Article

References (35)

1. Mizuguchi H, Xu ZL, Sakurai F, Mayumi T, Hayakawa T (2003) Tight positive regulation of transgene expression by a single adenovirus vector containing the rtTA and tTS expression cassettes in separate genome regions. Hum Gene Ther 14:1265-1277
2. Chong H, Ruchatz A, Clackson T, Rivera VM, Vile RG (2002) A system for small-molecule control of conditionally replication-competent adenoviral vectors. Mol Ther 5:195-203
3. Karns LR, Kisielewski A, Guiding KM, Seraj JM, Theodorescu D (2001) Manipulation of gene expression by an ecdysone-inducible gene switch in tumor xenografts. BMC Biotechnol 1:11
4. Wieser C, Stumpf D, Grillhosl C, Lengenfelder D, Gay S, Fleckenstein B, Ensser A (2005) Regulated and constitutive expression of anti-inflammatory cytokines by nontransforming herpesvirus saimiri vectors. Gene Ther 12:395-406
5. Salucci V, Scarito A, Aurisicchio L, Lamartina S, Nicolaus G, Giampaoli S, Gonzalez-Paz O, Toniatti C, Bujard H, Hillen W, Ciliberto G, Palombo F (2002) Tight control of gene expression by a helper-dependent adenovirus vector carrying the rtTA2(s)-M2 tetracycline transactivator and repressor system. Gene Ther 9:1415-1421
6. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H (1995) Transcriptional activation by tetracyclines in mammalian cells. Science 268:1766-1769
7. Gossen M, Bujard H (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 89:5547-5551
8. Lamartina S, Silvi L, Roscilli G, Casimiro D, Simon AJ, Davies ME, Shiver JW, Rinaudo CD, Zampaglione I, Fattori E, Colloca S, Gonzalez PO, Laufer R, Bujard H, Cortese R, Ciliberto G, Toniatti C (2003) Construction of an rtTA2(s)-m2/tts(kid)-based transcription regulatory switch that displays no basal activity, good inducibility, and high responsiveness to doxycycline in mice and non-human primates. Mol Ther 7:271-280
9. Fechner H, Wang X, Srour M, Siemetzki U, Seltmann H, Sutter AP, Scherubl H, Zouboulis CC, Schwaab R, Hillen W, Schultheiss HP, Poller W (2003) A novel tetracycline-controlled transactivator-transrepressor system enables external control of oncolytic adenovirus replication. Gene Ther 10:1680-1690
10. Srour MA, Fechner H, Wang X, Siemetzki U, Albert T, Oldenburg J, Hanfland P, Poller W, Brackmann HH, Schwaab R (2003) Regulation of human factor IX expression using doxycycline-inducible gene expression system. Thromb Haemost 90:398-405
11. Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W (2000) Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci U S A 97:7963-7968
12. Freundlieb S, Schirra-Muller C, Bujard H (1999) A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells. J Gene Med 1:4-12
13. McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ (2003) Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 10:2112-2118
14. Agha-Mohammadi S, O'Malley M, Etemad A, Wang Z, Xiao X, Lotze MT (2004) Second-generation tetracycline-regulatable promoter: repositioned let operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness. J Gene Med 6:817-828
15. Rubinchik S, Woraratanadharm J, Yu H, Dong JY (2005) New complex Ad vectors incorporating both rtTA and tTS deliver tightly regulated transgene expression both in vitro and in vivo. Gene Ther 12:504-511
16. Pluta K, Luce MJ, Bao L, Agha-Mohammadi S, Reiser J (2005) Tight control of transgene expression by lentivirus vectors containing second-generation tetracycline-responsive promoters. J Gene Med 7:803-817
17. Gafni Y, Pelled G, Zilberman Y, Turgeman G, Apparailly F, Yotvat H, Galun E, Gazit Z, Jorgensen C, Gazit D (2004) Gene therapy platform for bone regeneration using an exogenously regulated, AAV-2-based gene expression system. Mol Ther 9:587-595
18. Hurtado Picó A, Wang X, Sipo I, Siemetzki U, Eberle J, Poller W, Fechner H (2005) Viral and nonviral factors causing nonspecific replication of tumor- and tissue-specific promoter-dependent oncolytic adenoviruses. Mol Ther 11:563-577
19. Rang A, Will H (2000) The tetracycline-responsive promoter contains functional interferon-inducible response elements. Nucleic Acids Res 28:1120-1125
20. Hedlund TE, Meech SJ, Srikanth S, Kraft AS, Miller GJ, Schaack JB, Duke RC (1999) Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. Cell Death Differ 6:175-182
21. Shinoura N, Yoshida Y, Sadata A, Hanada KI, Yamamoto S, Kirino T, Asai A, Hamada H (1998) Apoptosis by retrovirus- and adenovirus-mediated gene transfer of Fas ligand to glioma cells: implications for gene therapy. Hum Gene Ther 9:1983-1993
22. Hyer ML, Sudarshan S, Schwartz DA, Hannun Y, Dong JY, Norris JS (2003) Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression. Cancer Gene Ther 10:330-339
23. Eberle J, Fecker LF, Hossini AM, Wieder T, Daniel PT, Orfanos CE, Geilen CC (2003) CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xeno-transplants. Oncogene 22:9131-9141
24. Rom WN, Hay JG, Lee TC, Jiang Y, Tchou-Wong KM (2000) Molecular and genetic aspects of lung cancer. Am J Respir Crit Care Med 161:1355-1367
25. Brown JR, DuBois RN (2004) Cyclooxygenase as a target in lung cancer. Clin Cancer Res 10:4266s-4269s
26. Hyer ML, Voelkel-Johnson C, Rubinchik S, Dong J, Norris JS (2000) Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Mol Ther 2:348-358
27. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759-1762
28. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Botstein D, Ashkenazi A (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396:699-703
29. Nambu Y, Hughes SJ, Rehemtulla A, Hamstra D, Orringer MB, Beer DG (1998) Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest 101:1102-1110
30. Kawasaki M, Kuwano K, Nakanishi Y, Hagimoto N, Takayama K, Pei XH, Maeyama T, Yoshimi M, Kara N (2000) Analysis of Fas and Fas ligand expression and function in lung cancer cell lines. Eur J Cancer 36:656-663
31. Doronin K, Kuppuswamy M, Toth K, Tollefson AE, Krajcsi P, Krougliak V, Wold WS (2001) Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J Virol 75:3314-3324
32. Sipo I, Wang, X Hurtado Picó A, Suckau L, Weger S, Poller W, Fechner H (2005) Tamoxifen-regulated adenoviral E1A chimeras for the control of tumor selective oncolytic adenovirus replication in vitro and in vivo. Gene Ther (in press). DOI 10.1038/sj.gt.3302604
33. Fechner H, Wang X, Wang H, Jansen A, Pauschinger M, Scherubl H, Bergelson JM, Schultheiss HP, Poller W (2000) Transcomplementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells. Gene Ther 7:1954-1968
34. Zouboulis CC, Seltmann H, Neitzel H, Orfanos CE (1999) Establishment and characterization of an immortalized human sebaceous gland cell line (SZ95). J Invest Dermatol 113:1011-1020
35. Marienfeld U, Haack A, Thalheimer P, Schneider-Rasp S, Brackmann HH, Poller W (1999) 'Autoreplication' of the vector genome in recombinant adenoviral vectors with different E1 region deletions and transgenes. Gene Ther 6:1101-1113